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In the enhancer region of the human type I collagen alpha 2 (COL1A2) gene, we identiﬁed cis-elements
for the transcription factor CUX1. However, the role of CUX1 in ﬁbrosis remains unclear. Here we in-
vestigated the role of CUX1 in the regulation of COL1 expression and delineated the mechanisms un-
derlying the regulation of COL1A2 expression by CUX1 in systemic sclerosis (SSc) lung ﬁbroblasts. The
binding of CUX1 to the COL1A2 enhancer region was assessed using electrophoretic mobility shift assays
after treatment with transforming growth factor (TGF)-β. Subsequently, the protein expression levels of
CUX1 isoforms were determined using Western blotting. Finally, the expression levels of COL1 and ﬁ-
brosis-related cytokines, including CTGF, ET-1, Wnt1 and β-catenin were determined. The binding of
CUX1 isoforms to the COL1A2 enhancer region increased after TGF-β treatment. TGF-β also increased the
protein levels of the CUX1 isoforms p200, p150, p110, p75, p30 and p28. Moreover, SSc lung ﬁbroblasts
showed higher levels of CUX1 isoforms than normal lung ﬁbroblasts, and treatment of SSc lung ﬁbro-
blasts with a cathepsin L inhibitor (IW-CHO) decreased COL1 protein expression and reduced cell size, as
measured using immunocytochemistry. In SSc and diffuse alveolar damage lung tissue sections, CUX1
localised within α-smooth muscle actin-positive cells. Our results suggested that CUX1 isoforms play
vital roles in connective tissue deposition during wound repair and ﬁbrosis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Scleroderma, or systemic sclerosis (SSc), is a connective tissue
disease characterised by excessive type I collagen (COL1) deposi-
tion in many organs including the lungs, kidneys and skin [1].
Approximately 40% patients with diffuse SSc experience pulmon-
ary ﬁbrosis, a major cause of mortality [1]. Although the aetiology
of this disease is poorly understood, tissue scarring occurs after
injury following the release of several mediators including TGF-β,
PDGF, CTGF, Wnt1 and ET-1 [2–6]. These factors stimulate ﬁbro-
blasts to differentiate into myoﬁbroblasts, which are characterisedB.V. This is an open access article u
-β; CTGF, connective tissue
pe MMTV integration site
or; α-SMA, α-smooth muscle
te of Medical Science, Uni-
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eda).by the expression of α-SMA and excessive production of extra-
cellular matrix molecules such as COL1 [7,8]. Overexpression of
these cytokines results in chronic ﬁbroblast stimulation (ﬁbrosis).
Moreover, genetically modiﬁed mice with altered TGF-β signalling
have been reported to exhibit ﬁbrogenic pathology similar to that
observed in patients with SSc, indicating a key role of this cytokine
in the pathogenesis of ﬁbrosis [9–11]. Elucidation of pivotal med-
iators or key signalling pathways that are overactive in ﬁbrosis is
crucial for designing better therapeutic strategies for SSc and re-
lated disorders.
TGF-β is a potent pro-ﬁbrotic cytokine that promotes myoﬁ-
broblast differentiation, migration, extracellular matrix synthesis
and apoptosis resistance [12–14]. TGF-β induces the expression of
the gene encoding human collagen type I alpha 2 (COL1A2) via a
Smad-dependent pathway that acts on a TGF-β responsive ele-
ment (TbRE) in the human COL1A2 proximal promoter [15,16].
COL1 expression in vivo is exclusively controlled by an enhancer
sequence that contains several DNase I hypersensitive sites (HSs).
These encompass pivotal regulatory sites conferring tissue-, tem-
poral-, cell- and growth factor-speciﬁc expression of COL1 [15,16].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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COL1A2 via a non-canonical Smad-independent pathway, which
requires enhancer/promoter cooperation. Moreover, we identiﬁed
a novel TbRE in the human COL1A2 enhancer region and found
that it is necessary for COL1A2 activation [16]. Further, we reported
that high doses of TGF-β increased CUX1 binding in the proximal
promoter and suppressed COL1 expression [17].
In this study, we identiﬁed CUX1 binding sites near this TbRE of
the COL1A2 enhancer region using in silico analyses. These sites
exist at identity island 4 (IS4) near HS4 in the enhancer region [18]
In addition, this study demonstrated that CUX1 responds to TGF-β
stimulation and is a potential activator of COL1. Based on these
ﬁndings, we characterised the role of human CUX1 in the reg-
ulation of COL1 expression and subsequent release of pro-ﬁbrotic
cytokines. We demonstrated that some isoforms of human CUX1
are strongly induced after TGF-β stimulation, which results in the
up-regulation of CTGF, Wnt1, ET-1, β-catenin and COL1 in vitro. In
addition, we investigated the expression pattern of human CUX1
isoforms in lung ﬁbroblasts derived from normal cells and patients
with SSc. In lung ﬁbroblasts derived from patients with SSc, pro-
tein levels of the CUX1 isoforms p200, p150, p110, p75, p30 and
p28 were increased compared with those in normal cells. Using
electrophoretic mobility shift assays (EMSAs) with nuclear extracts
from these cells, we demonstrated that CUX1 binding to the
COL1A2 enhancer region was increased. Cleavage sites for cathe-
psin L have been found between CR1 and CR2 and those for cas-
pases have been identiﬁed between CR3 and HR of CUX1 [19].
Therefore, we conﬁrmed whether cathepsin L inhibitor (IW-CHO)
can regulate COL1. IW-CHO inhibited COL1 in both normal and SSc
lung ﬁbroblasts. Taken together, our data strongly suggest that
CUX1 isoforms up-regulate COL1 and regulate key pro-ﬁbrotic
activities of TGF-β. Our results could provide novel insights into
CUX1-mediated regulation of COL1A2 in human lung ﬁbroblasts.
These results are an important contribution to the understanding
of processes involved in SSc-associated ﬁbrosis.2. Materials and methods
2.1. Cell culture
Cells were maintained in DMEM supplemented with 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin and cultured in a
humidiﬁed atmosphere of 5% CO2. We isolated lung ﬁbroblasts as
previously described [20]. The cells were cultured under standard
conditions in DMEM containing 10% FBS. Pulmonary ﬁbroblasts
were obtained from patients who fulﬁlled the criteria of the
American College of Rheumatology for the diagnosis of SSc with
lung involvement. Informed consent and ethical approval were
obtained. None of the patients was receiving immunosuppressive
medication or corticosteroids at the time of biopsy.
2.2. Western blotting
Nuclear extracts and cytosolic fractions were prepared as pre-
viously described [16]. The cells were washed with phosphate-
buffered saline (PBS) and treated with Laemmli sample buffer. To
analyse collagen, the medium was removed and adjusted to 20%
(v/v) ammonium sulphate, followed by incubation at 4 °C over-
night. The samples were centrifuged, and the pellet was re-sus-
pended in Laemmli sample buffer with β-mercaptoethanol for
SDS-PAGE, followed by Western blotting. The following antibodies
were used: lamin A/C (sc20681, Santa Cruz), COL1 (rabbit anti-
mouse collagen 1, ref 20151, Novotec), ET-1 (T4049, Peninsula),
CUX1 (M-222, sc-13024, Santa Cruz), CTGF (L-20, sc14939, Santa
Cruz), GAPDH (ab8245-100, Abcam), β-catenin (ab6302-100,Abcam) and Wnt1 (anti-human WNT1 S#500-p250, PeproTech,
Inc.).
N-(1-naphthalenylsulfonyl)-Ile-Trp-aldehyde (IW-CHO, 0.2 μM,
Alexis Biochemicals) was used as IW-CHO. TGF-β (R&D Systems)
was used at 4 ng/ml. The cells were serum-starved for 12 h and
incubated with or without TGF-β at 4 ng/ml for a further 24 h.
2.3. Plasmid transfection
Cells were seeded in six-well plates before transfection and
24 h later were transfected using FuGENE 6 (Roche, Basel, Swit-
zerland), according to the manufacturer's instructions; this
method was used to transfect sh-CUX1 vector as described pre-
viously [17].
2.4. EMSAs
Nuclear extracts were prepared from ﬁbroblasts obtained from
patients with SSc using a previously described method [16].
Brieﬂy, double-stranded oligonucleotides were synthesised, end-
labelled with 32P-gamma-ATP using T4 kinase and used in binding
reactions with nuclear extracts from the cells. Competition was
performed with unlabelled oligonucleotides (1.75 pmol/ml). Oli-
gonucleotides for the CUX1-19.51 kb probe (5′-attggcagtgagttact-
tagta-3′) were used. We employed the standard conditions re-
commended by the kit manufacturer (Promega) and separated the
reaction on a 4% polyacrylamide gel at 4 °C and 160 V. Consensus
oligonucleotides for CUX1 (CDP, sc2593, Santa Cruz) and SP1 (sc-
2502, Santa Cruz) were used.
2.5. Immunocytochemistry
The cells were washed in ice-cold PBS twice and ﬁxed with 3%
paraformaldehyde in PBS for 15 min at room temperature. The
cells were blocked with 3% BSA for 30 min at 25 °C, followed by
incubation with CUX1 antibody (0.2 mg/ml) and monoclonal anti-
α-SMA clone 1a Cy3-conjugated antibody (0.7 mg/ml) (Sigma-Al-
drich) overnight at 4 °C. Subsequently, the cells were washed with
ice-cold PBS twice, incubated with an Alexa 488 secondary anti-
body overnight at 4 °C, washed with ice-cold PBS twice and in-
cubated with DAPI (Roche) for 30 min at room temperature. Slides
were viewed and photographed using a Zeiss Axioscope light
microscope (Carl Zeiss, Göttingen, Germany) with Axiovision
software.
2.6. Immunohistochemistry
For formalin-ﬁxed parafﬁn-embedded specimens, tissues were
ﬁxed and hydrated as previously described [10]. For im-
munohistochemistry, sections were pre-treated with methanol
(VWR, Lutterworth, UK), followed by antigen retrieval in heated
10 mM citrate buffer (pH 6). The primary antibodies were CUX1
antibody (0.2 mg/ml) and monoclonal anti-α-SMA clone 1a Cy3-
conjugated antibody (0.7 mg/ml). Sections were sequentially in-
cubated with a 1/200 dilution of an Alexa 488 secondary antibody.
Slides were viewed and photographed using a Zeiss Axioscope
light microscope with Axiovision software.
2.7. Data analysis
Data are expressed as the mean7S.E of at least three in-
dependent experiments. Statistical analysis was performed using
Student's t-test. Values of Po0.05 were considered signiﬁcant.
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3.1. CUX1 binds to the enhancer region of human COL1A2
The CUX1 cis-element CCAAT (Fig. 1A) was identiﬁed at IS4
near enhancer-containing DNase I HS4 using in silico analyses. Cut
repeats and homeodomains bind to this cis-element (Fig. 1A) [21].
To determine whether CUX1 interacts with the enhancer region of
human COL1A2, we performed EMSAs using transcription factor-
binding consensus oligonucleotides, CUX1 antibody and sh-CUX1.
In these experiments, we not only veriﬁed the binding of CUX1 at
CUX1 (19.51 kb) probe sites but also demonstrated the binding
of several other transcription factors, including JunD (data not
shown). Nuclear extracts from normal lung ﬁbroblasts incubated
with or without TGF-β were used, and CUX1 consensus oligonu-
cleotides, CUX1 antibody and sh-CUX1 decreased the intensity of
CUX1 bands (Fig. 1B). Furthermore, the binding of CUX1 at CUX1
(19.51 kb) probe sites increased post-TGF-β treatment in both
normal and SSc lung ﬁbroblasts (Fig. 2A).
3.2. TGF-β up-regulates the expression of CUX1 isoforms
CUX1, also known as CCAAT displacement protein (CDP),
CUTL1, CUT or Cux, belongs to a family of homeobox transcription
factors that are involved in the regulation of cell growth and dif-
ferentiation [22]. It is evolutionarily conserved and comprises four
DNA binding domains, three of which are known as Cut repeats
and one is known as the Cut homeodomain [21]. CUX1 mainly acts
as a transcriptional repressor, but it can also act as an activator
[23–25]. Transgenic mice with CUX1 overexpression have beenFig. 1. Electrophoretic mobility shift assays (EMSAs) revealed that CUX1 binds to the hum
upstream enhancer region (FUE) with arrows indicating known DNase hypersensitive sit
elements are indicated by bold letters. B. EMSA using the CUX1 (19.51 kb) probe. NE, n
several bands detected using P32-labelled oligos in Lanes 2 and 3. Bands were conﬁrme
4 and 5. Consensus oligo for CUX1, Lanes 8–9. Consensus oligo for SP1, Lanes 6–7. Antibreported to exhibit multi-organ hyperplasia and organomegaly
[26]. Moreover, the CUX1 isoforms p200 and p110 can regulate
motility and invasiveness through a TGF-β-dependent mechanism
[27,28]. However, the role of CUX1 isoforms in the development of
ﬁbrosis remains unclear. We performed Western blotting to de-
termine whether the expression levels of CUX1 isoforms were
induced by TGF-β. We found that the expression levels of CUX1
isoforms signiﬁcantly increased in both normal and SSc lung ﬁ-
broblasts post-TGF-β treatment (Fig. 2B, C). TGF-β treatment re-
sulted in the induction of p200 and p150 in normal lung ﬁbro-
blasts. Moreover, TGF-β treatment resulted in the induction of
p200, p150, p110, p75, p30 and p28 in SSc lung ﬁbroblasts. These
results suggested that TGF-β stimulate the expression of CUX1
isoforms. We also veriﬁed whether the expression levels of pro-
ﬁbrotic proteins were up-regulated. ET-1, COL1, Wnt1, CTGF and β-
catenin levels increased post-TGF-β treatment in normal and SSc
lung ﬁbroblasts (Fig. 2D).
3.3. Effects of cathepsin L inhibition on lung ﬁbroblasts derived from
patients with SSc
Several studies have illustrated that CUX1 is cleaved into p150,
P110, p75 and other subunits by nuclear cathepsin L. To conﬁrm
the effects of cathepsin L inhibition on SSc lung ﬁbroblasts, we
measured the expression levels of COL1 in both normal and SSc
lung ﬁbroblasts. IW-CHO (0.2 μM) was used because its IC50 is
1.9 nM. IW-CHO decreased the expression levels of COL1 in normal
and SSc lung ﬁbroblasts (Fig. 2E). To further conﬁrm the effects of
cathepsin L on SSc lung ﬁbroblasts, we used im-
munocytochemistry to study CUX1 localization in thesean type I collagen alpha 2 gene (COL1A2) enhancer. A. Schematic diagrams of the far
es; the white box indicates the known identity islands of human COL1A2. CUX1 cis-
uclear extract from normal lung ﬁbroblasts. The right-hand graph of Fig. 1B shows
d using a cold competitor. Unlabelled competing oligo probes are shown in Lanes
ody for CUX1, Lanes 11–13. Sh-CUX1, Lanes 15. FP, free probe.
Fig. 2. CUX1 isoforms in normal human and systemic sclerosis (SSc) lung ﬁbroblasts. A. Electrophoretic mobility shift assay using normal lung ﬁbroblast (N) nuclear extract
(NE) (Lanes 1–2) and SSc lung ﬁbroblast NE (Lanes 3–4) treated with transforming growth factor (TGF)- β (Lanes 2 and 4) or untreated (Lanes 1 and 3) for the CUX1
(19.51 kb) probe. FP, free probe. B. Effects of TGF-β on the expression of CUX1 isoforms as assessed using Western Blotting. TGF-β (4 ng/ml) was added to the ﬁbroblasts
after 12 h of serum starvation. Then, the cells were cultured for 24 h. C. Graphs represent the results of Fig. 2B. D. Effects of TGF-β on the expression of collagen type I and
ﬁbrosis-related proteins. Several ﬁbrosis-related cytokines and proteins were detected using the cytosolic fraction as well as the medium and NEs from both normal and SSc
lung ﬁbroblasts with or without TGF-β treatment. E. Effects of a cathepsin L inhibitor (IW-CHO, 0.2 mM) and sh-CUX1 on the expression of type I collagen (COL1) in normal
and SSc lung ﬁbroblasts. Values represent mean7S.E.M., n¼3. *, signiﬁcantly different from control, Po0.05 by Student's t-test. GAPDH and lamin A/C were used as internal
controls.
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dicated that SSc lung ﬁbroblasts were CUX1- and α-SMA-positive,
with positivity increasing post-TGF-β treatment. CUX1 localised to
the nucleus and cytosol. In addition, SSc lung ﬁbroblasts were
larger than normal lung ﬁbroblasts (data not shown). IW-CHO
decreased the CUX localization in the nucleus and reduced the
large size of SSc lung ﬁbroblasts with or without TGF-β treatment
(Fig. 3).3.4. Immunohistochemical analyses of SSc and diffuse alveolar da-
mage (DAD) lung tissue sections stained with antibodies against
CUX1 and α-SMA
Immunocytochemistry revealed the presence of α-SMA-posi-
tive ﬁbrotic loci (Fig. 4), which is characteristic of patients with SSc
and DAD. CUX1 localised at alveolar cells and ﬁbrotic loci. In ad-
dition, CUX1 localised within α-SMA-positive cells (Fig. 4,
merged).4. Discussion
This study demonstrated the binding of CUX1 to the IS4 do-
main of the COL1A2 enhancer region in both normal and SSc lung
ﬁbroblasts. Further, our results demonstrated that TGF-β-induced
CUX1 isoforms function as transcriptional activators that increase
the expression of COL1 proteins. Previous studies implicated CUX1
in both the activation and suppression of several genes [23–25].
Our previous study found that CUX1 bound to the proximal pro-
moter of COL1A2 after treatment with high doses of TGF-β [22]. In
this study, we provide evidence that CUX1 also plays a major role
in COL1A2 activation both in vitro and ex vivo via the IS4 domain of
the COL1A2 enhancer.
Our data clearly demonstrated that TGF-β induces the expres-
sion of CUX1 isoforms, some of which were also up-regulated in
SSc lung ﬁbroblasts. In association with this change, the binding of
CUX1 to the enhancer region of human COL1A2 increased in re-
sponse to TGF-β treatment in normal and SSc lung ﬁbroblasts.
These results suggested that TGF-β up-regulates CUX1 protein
expression, resulting in an increased binding of CUX1 to the hu-
man COL1A2 enhancer and COL1 up-regulation.
Fig. 3. Effects of IW-CHO on systemic sclerosis (SSc) lung ﬁbroblasts. Immunoﬂuorescence analysis performed using SSc lung ﬁbroblasts treated with or without TGF-β. Cells
were stained using CUX1 antibody, DAPI and α-SMA antibody. IW-CHO treatment decreased the CUX localization in the nucleus and reduced the size of lung ﬁbroblasts in
patients with SSc. In addition, in the presence of TGF-β, IW-CHO treatment reduced the size of lung ﬁbroblasts in patients.
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the expression of the CUX1 isoforms p200, p150, p110, p75, p30
and p28 in SSc lung ﬁbroblasts. Cleavage sites have been found for
cathepsin L between CR1 and CR2 and for caspase between CR3
and HR of CUX1 [19]. Previous studies have revealed the induction
of HA-tagged CUX-1 p200 and p110 in certain cell lines [19,29].
The CUX-1 antibody M-222 simultaneously recognises several
CUX1 isoforms in normal and SSc lung ﬁbroblasts following TGF-β
treatment. As the molecular weight patterns observed in our study
are similar to those previously reported, we believe that all bands
observed in this study were speciﬁc for CUX1 isoforms.
Our data provide further evidence that CUX1 isoforms may play
crucial roles in COL1A2 regulation. First, the levels of all CUX1
isoforms increased in SSc lung ﬁbroblasts compared with the le-
vels in normal lung ﬁbroblasts. Moreover, compared with the
ﬁndings in normal lung ﬁbroblasts, data from EMSA revealed
signiﬁcantly increased binding of CUX1 at CUX1 (19.51 kb) probe
sites of human COL1A2 in SSc lung ﬁbroblasts. Several reports
studies have illustrated that CUX1 isoforms have different DNA
binding afﬁnities and functions [19,23–25,30]. Second, COL1 ex-
pression decreased by cathepsin L inhibition in normal and SSc
lung ﬁbroblasts, highlighting the importance of CUX1 isoforms in
ﬁbrosis. Third, CUX1 localised at the nucleus and cytosol (Fig. 3).
CUX1 and α-SMA co-localised in the cytosol in SSc lung ﬁbroblasts.IW-CHO decreased the CUX localization in the nucleus and re-
pressed the large size of SSc lung ﬁbroblasts with or without TGF-
β treatment (Fig. 3). In addition, in SSc and DAD lung sections,
CUX1 localised around ﬁbrotic loci and alveolar cells. Some of
these cells were stained by both CUX1 and α-SMA (Fig. 4). Fur-
thermore, in the SSc skin and idiopathic pulmonary ﬁbrosis (IPF)
sections, CUX1 localised within and around α-SMA positive cells
(See Figs. 1 and 2, reference [31]). These results indicated that
CUX1 isoforms are necessary for ﬁbrosis.
In future, investigations on the mutagenesis of CUX1 cleavage
sites are required to determine which CUX1 isoforms are crucial. In
addition, we need to verify the effects of CUX1 isoforms on the
promoter region of α-SMA and pro-ﬁbrotic cytokines. We spec-
ulate that some speciﬁc features of CUX1 isoforms are important
for the activation of human COL1A2 via the IS4 domain, which is
located in the COL1A2 enhancer.
In summary, our study demonstrated that the up-regulation of
CUX1 isoforms is associated with ﬁbrosis in vitro in SSc lung ﬁ-
broblasts as well as in tissue sections from patients with SSc and
DAD. Hence, these data indicate that the expression of CUX1 iso-
forms is possibly important for ﬁbrosis and could be relevant to
the pathogenesis of SSc.
Fig. 4. Systemic sclerosis (SSc) and diffuse alveolar damage (DAD) lung tissue sections stained with antibodies against CUX1 and α-smooth muscle actin (SMA). The ﬁgure
shows ﬁbrotic loci that were stained by CUX1 and α-SMA antibodies. Alveolar cells around the loci were positive for CUX1 and α-SMA. CUX1 localised within α-SMA-positive
cells.
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